Exhibit 99.1 WW International, Inc. Announces First Quarter 2025 Results NEW YORK (May 6, 2025) – WW International, Inc. (NASDAQ: WW) ("WeightWatchers," "WW," or the "Company") today announced its results for the first quarter of fiscal 2025 ended March 29, 2025. "We are making progress on our strategic priorities with continued momentum in our Clinical business, while laying the foundation for long-term, sustainable growth," said Tara Comonte, President and CEO. "As the weight management landscape evolves, ...

Core Insights - WW International, Inc. reported a net loss of $72.6 million for Q1 2025, a significant improvement from a net loss of $347.9 million in the same period last year, reflecting a 79.1% reduction in losses [9][10][16] - The company experienced a 9.7% decline in total revenues, amounting to $186.6 million, primarily due to challenges in the Behavioral business, despite a 57% year-over-year growth in Clinical revenue [3][10][9] - Adjusted EBITDAS increased to $26.9 million, up 274% year-over-year, indicating improved operational efficiency and cost management [9][10][16] Financial Performance - Subscription revenues decreased by 9.3% to $185.2 million, with Clinical subscription revenues rising by 57.1% to $29.5 million [3][10][9] - Gross profit was $132.9 million, down 3.6% from the previous year, while the gross margin improved to 71.2%, up 450 basis points [9][10][16] - The company reported an adjusted EPS of -$0.47, compared to -$1.29 in the prior year, marking a 63.7% improvement [9][10][16] Subscriber Metrics - Total end-of-period subscribers decreased by 14.2% to 3.4 million, with a notable 55.2% increase in Clinical subscribers to 135,000 [9][10][10] - Digital subscribers fell by 14.7% to 2.8 million, while Workshops + Digital subscribers decreased by 21.1% to 0.5 million [9][10][10] - Subscription revenues per paid week increased by 4.8% to $4.13, driven by growth in the Clinical business [9][10][10] Strategic Initiatives - The company is focusing on delivering a unified member experience, revitalizing its brand, and expanding adjacent revenue streams [2][10] - WW International is engaged in discussions with lenders to restructure its capital and reduce debt, with a potential prepackaged filing under Chapter 11 anticipated imminently [9][10][16] - The management emphasizes the importance of operational excellence and efficiency to stabilize the business and return to growth [2][10]

Core Insights - WeightWatchers has announced a pharmacy integration with Gifthealth to enhance access to Zepbound® for its clinic members [1][2] - The integration aims to streamline the fulfillment process and improve medication visibility for eligible members [2][3] Company Overview - WeightWatchers is a leader in science-backed weight management, providing a holistic model of care that includes clinical interventions and community support [4] - The company has been transforming lives for over 60 years, empowering millions of members to build healthy habits [4] Integration Details - The integration with Gifthealth allows for real-time prescription tracking and streamlined access to Zepbound® vials for self-pay patients without insurance [2][3] - Zepbound® usage among WeightWatchers Clinic members has increased significantly, with 33% currently using it and prescriptions for Zepbound vials rising over 100% recently [3] Clinical Impact - A study of 3,260 WeightWatchers Clinic patients showed an average weight loss of 21% at 12 months, indicating the effectiveness of combining GLP-1 medications like Zepbound with WeightWatchers' lifestyle support [3]

Core Viewpoint - WW International, known as WeightWatchers, is preparing to file for bankruptcy to transfer control of the business to its creditors, with shares plummeting nearly 59% to 18 cents [1]. Company Summary - The company has struggled to remain relevant due to the rise of effective weight-loss drugs like Novo Nordisk's Wegovy, which provide quicker solutions to obesity [2]. - WeightWatchers is currently negotiating with lenders and bondholders, a process that is not related to market conditions or tariffs [3]. - The firm, which previously offered nutrition and behavior-change programs, acquired the subscription-based telehealth platform Sequence in 2023 to expand into obesity drug prescriptions [3]. - WeightWatchers' stock, which peaked at $100 in 2018, has significantly declined due to revenue drops, liquidity issues, and the departure of celebrity shareholder Oprah Winfrey from its board [4]. - The company has also faced challenges from competing weight-loss drugs like Ozempic [6].

Subscriber and Revenue Trends - The company had approximately 2.7 million Digital subscribers and 0.5 million Workshops + Digital subscribers by the end of fiscal 2024[34][35]. - The Clinical business, launched in 2023, had around 0.1 million Clinical subscribers by the end of fiscal 2024[38]. - Sales of consumer products represented approximately 6.2% of total revenues in fiscal 2023, but the company decided to close this lower-margin business[32]. - Total revenues for fiscal 2024 decreased by 11.6% to $785.9 million compared to $889.6 million in fiscal 2023[221]. - Subscription revenues for fiscal 2024 decreased by 5.6% to $777.0 million, primarily due to a decline in Digital Subscription Revenues and Workshops + Digital Subscription Revenues[222]. - Other revenues for fiscal 2024 decreased by 86.6% to $8.9 million, primarily driven by the closure of the consumer products business at the end of fiscal 2023[222]. - End of Period Subscribers for fiscal 2024 decreased by 12.2% compared to the prior year, indicating challenges in recruitment and retention[222]. Business Strategy and Market Position - The company’s GLP-1 Program was launched in the U.S., U.K., and Germany in December 2023, targeting individuals taking GLP-1 medications[27]. - The company’s behavior change programs are supported by over 180 peer-reviewed scientific studies, demonstrating their effectiveness[40]. - The company was recognized by U.S. News & World Report as the 1 "Best Weight-Loss Diet" for the fifteenth consecutive year in 2025[43]. - The company’s marketing strategy leverages data-driven approaches and social media engagement to attract new and returning members[44][45]. - The company’s business is seasonal, with the highest member recruitment typically occurring in the first quarter of the year[46]. - The company’s subscriber base is crucial for revenue generation, and future growth depends on retaining and expanding this base[76]. - The company’s future success relies on its ability to innovate and respond to changing consumer demands in the weight management sector[79]. Acquisitions and Partnerships - The acquisition of Sequence, a telehealth platform, was completed on April 10, 2023, expanding the company's offerings to include clinical interventions and addressing consumer demand for GLP-1 medications[52]. - The company completed the acquisition of Weekend Health, Inc. in 2023, but future acquisitions may face challenges in terms of integration and market perception, which could adversely affect financial performance[101]. - The company has a strategic collaboration agreement with Ms. Winfrey, which includes her consulting on program development and marketing initiatives[54]. - The acquisition of Sequence on April 10, 2023, is expected to generate revenue synergies and operating efficiencies, but achieving these benefits is uncertain[161]. Financial Health and Debt Management - As of December 28, 2024, the company's total debt was $1,445.0 million, with an additional $171.3 million borrowed in January 2025, leading to a significant exposure to variable interest rates[111]. - The company's consolidated first lien secured net leverage ratio was 8.36:1.00 as of December 28, 2024, exceeding the required ratio of 5.25:1.00, which may lead to default under the Revolving Credit Facility[114]. - The company made a significant cash payment of $16.0 million related to the acquisition of Sequence, impacting its liquidity in fiscal 2025[119]. - The company is actively evaluating its capital structure and intends to engage with lenders to strengthen its balance sheet by reducing leverage and interest expenses[118]. - The company may not be able to generate sufficient cash to service all of its debt obligations, which could impact its liquidity and financial flexibility[117]. Regulatory and Compliance Challenges - The company must navigate a complex regulatory landscape regarding its clinical offerings, particularly concerning compounded medications[81]. - The company is committed to monitoring and complying with evolving laws and regulations affecting its operations and advertising practices[59]. - The healthcare industry is subject to extensive and complex laws and regulations, which may lead to civil or criminal penalties if not complied with[139]. - The regulatory landscape for telehealth services is constantly evolving, which may result in increased compliance costs and operational impacts[144]. - The company may face significant monetary penalties under the Federal Civil False Claims Act for submitting false claims[150]. Cybersecurity and Data Privacy - The company has developed a comprehensive cybersecurity program to protect confidential information and mitigate risks associated with cybersecurity threats[176]. - The company is subject to evolving data privacy regulations, such as GDPR and CCPA, which could increase compliance costs and impact operations[125]. - The company maintains cybersecurity insurance, but costs related to cybersecurity threats may not be fully covered[182]. - The company has a cybersecurity management team that includes the CISO, Data Privacy Officer, CLRO, CFO, and Head of Internal Audit, which meets regularly to review cybersecurity strategies and risk posture[179]. Leadership and Workforce - The company has approximately 3,700 employees across 11 countries as of December 31, 2024, with a majority being part-time employees[62]. - All current executive officers, including the CEO and CFO, are women, reflecting the company's commitment to diversity and inclusion[63]. - The executive team includes Tara Comonte as President and CEO, Felicia DellaFortuna as CFO, and Donna Boyer as Chief Product Officer, among others[190]. - Tara Comonte has over two decades of executive leadership experience and previously served as CEO of TMRW Life Sciences[192]. Market Competition and Challenges - The company faces significant competition in the weight management and health and wellness market, which includes various service providers and products[73]. - The clinical weight management market is rapidly evolving, with increased competition from telehealth providers and traditional healthcare entities[74]. - The company is continually evaluating the changing consumer and competitive environment in the weight management and health and wellness marketplaces[83]. - The company faces risks related to the performance of collaboration partners, which could impact the success of its Clinical business and overall financial condition[102].

Financial Data and Key Metrics Changes - Q4 2024 revenue totaled $184 million, down 10% year-over-year, reflecting continued headwinds in digital and workshop businesses and the closure of the consumer products business [55][48] - Full year 2024 revenue was $786 million, a decline of 12% compared to the prior year, but above prior guidance of at least $770 million [48] - Adjusted gross margin was 69.1% in Q4, up from 61.4% in the prior year, driven by cost actions and the closure of the lower gross margin consumer products business [55][50] - Adjusted EBITDA margin was 27.4% in Q4, the highest level since Q3 2022 [40][50] Business Line Data and Key Metrics Changes - Behavioral business revenue declined 12%, while clinical business revenue grew by 58% [11] - Clinical subscribers increased to 92,000, growing 18% from Q3 and 38% year-over-year [48] - Subscription revenue overall was down 7% in Q4, with clinical revenue totaling $78 million [55][49] Market Data and Key Metrics Changes - The company entered 2025 with a revenue headwind of approximately $45 million due to a lower ending subscriber base in 2024 [14] - The clinical business is expected to drive future growth, with strong performance noted in Q4 and a strong start to Q1 2025 [28][49] Company Strategy and Development Direction - The company aims to stabilize and lay the groundwork for sustained future growth, focusing on improving the end-to-end member experience [15][17] - A commitment to removing $100 million in run rate costs by the end of 2025 has been established, with significant progress already made [15][37] - The integration of the Weekend Health acquisition is a priority, enhancing the continuum of care for members [18][20] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the existing capital structure and the need for investments to drive growth [16][42] - The company is optimistic about the long-term potential of the weight loss medication market, despite current supply challenges [32][30] - Management emphasized the importance of balancing short-term stability with long-term growth strategies [63][64] Other Important Information - The company ended 2024 with $53 million in cash and cash equivalents, with cash flow from operations being positive when excluding one-time restructuring payments and interest [51][54] - The company has engaged strategic advisers to assess its capital structure strategy moving forward [43] Q&A Session Summary Question: Trends during peak season and marketing environment - Management noted encouraging trends in product launches and engagement metrics, despite ongoing challenges in the behavioral business [67][70] Question: Importance of generic GLP-1 to clinic performance - The addition of compounded medications helped alleviate shortages and improve key metrics, with expectations for a return to branded medications as supply improves [78][80] Question: Avoiding a downward cycle with fewer subscribers - Management emphasized the value proposition of Weight Watchers and the need for innovation and product improvements to regain growth [90][92] Question: Subscriber growth and cash flow generation - Management indicated that while subscriber counts are challenged, the increase in average revenue per user (ARPU) is encouraging, and clinical subscriber growth is expected to continue [100][102] Question: Strategies regarding compounded semaglutide - Management expressed confidence in returning to branded medications as supply improves and is actively evaluating options for additional medications [106][112]

Financial Data and Key Metrics Changes - Revenue for Q4 2024 totaled $184 million, down 10% year-over-year, reflecting continued headwinds in digital and workshop businesses and the closure of the consumer products business [55][48] - Full year 2024 revenue was $786 million, a decline of 12% compared to the prior year, but above prior guidance of at least $770 million [48] - Adjusted gross margin was 69.1% in Q4, up from 61.4% in the prior year, driven by cost actions and the closure of the lower gross margin consumer products business [55][50] - Adjusted EBITDA margin was 27.4% in Q4, the highest level since Q3 2022 [40][50] Business Line Data and Key Metrics Changes - Behavioral business revenue declined 12% year-over-year, while clinical business revenue grew by 58% [11] - Clinical subscribers ended the year at 92,000, growing 18% from Q3 and 38% year-over-year [48] - Subscription revenue overall was down 7% in Q4, but the overall rate per paid week increased sequentially due to a higher mix of clinical subscribers [49] Market Data and Key Metrics Changes - The company entered 2025 with a revenue headwind of approximately $45 million, driven by a lower 2024 ending subscriber base [14] - The clinical business is expected to continue strong growth in January and February, despite potential volatility due to uncertainties surrounding compounded semaglutide [59] Company Strategy and Development Direction - The company is focused on stabilization, recovery, and rebuilding to lay the groundwork for sustained future growth [15][41] - Plans to remove $100 million in run rate costs by the end of 2025, with the majority already actioned [15][38] - Emphasis on improving the end-to-end member experience and integrating clinical and behavioral offerings [17][20] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by existing capital structure and the need for investments to drive growth [16][42] - The company is committed to providing medication access in compliance with laws and regulations, while monitoring the impact of FDA decisions on medication supply [32][30] - Management expressed confidence in the long-term potential of the weight loss medication market and the company's unique competitive position [15][33] Other Important Information - The company ended 2024 with $53 million in cash and cash equivalents, with cash flow from operations being positive when excluding one-time restructuring payments and interest payments [51][54] - The company has engaged strategic advisers to assess its capital structure strategy moving forward [43] Q&A Session Summary Question: Trends during peak season and marketing environment - Management noted challenges in the behavioral business but saw encouraging trends in clinical growth and product engagement [66][70] Question: Importance of clinical subscriber growth and GLP-1 medications - Management highlighted the positive impact of compounding on clinical metrics and the expectation of a return to branded medication supply [78][82] Question: Avoiding a downward cycle with fewer subscribers - Management emphasized the value proposition of WeightWatchers and the need for innovation and product improvements to regain growth [90][92] Question: Subscriber levels needed for cash flow - Management indicated that while subscriber counts are challenged, the increase in average revenue per user (ARPU) is encouraging [100][102] Question: Outcomes based on compounded semaglutide sales - Management expressed confidence in returning to branded medications as supply improves and highlighted ongoing evaluations of medication options [106][112]

分组1 - WW International reported quarterly earnings of $0.32 per share, exceeding the Zacks Consensus Estimate of a loss of $0.10 per share, and compared to a loss of $0.06 per share a year ago, representing an earnings surprise of 420% [1] - The company posted revenues of $184.41 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 3.43%, although this is a decrease from year-ago revenues of $205.96 million [2] - Over the last four quarters, WW International has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] 分组2 - WW International shares have declined approximately 42.9% since the beginning of the year, contrasting with the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.23 on revenues of $623.9 million, and -$0.21 on revenues of $721.64 million for the current fiscal year [7] - The Leisure and Recreation Services industry, to which WW International belongs, is currently ranked in the top 16% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Financial Performance - Q4 2024 revenues were $184.4 million, down 10.5% year-over-year, with Subscription Revenues at $181.7 million, a decline of 7.3%[5] - Full Year Fiscal 2024 revenues totaled $785.9 million, down 11.6% from the previous year, with Subscription Revenues at $777.0 million, a decrease of 5.6%[12] - Total revenues for the twelve months ended December 28, 2024, were $785,921, down 11.7% from $889,551 in 2023[34] - Total revenues for the full year 2024 were $785,921, a decrease of 11.6% compared to $889,551 in 2023[52] - Other revenues for the full year 2024 plummeted by 86.6% to $8,928 from $66,796 in 2023[52] Subscriber Metrics - Total End of Period Subscribers reached 3.3 million, a decrease of 12.2% compared to the prior year, with Clinical Subscribers increasing by 37.8% to 92 thousand[7] - Total End of Period Subscribers decreased to 3,336 as of December 28, 2024, down 12.2% from 3,798 in the same period of 2023[40] - Total Paid Weeks in Q4 2024 decreased by 9.9% year-over-year, with growth in Clinical Paid Weeks of 53.3% partially offsetting declines in other segments[7] - Total Paid Weeks in fiscal 2024 decreased by 5.1%, although Clinical Paid Weeks increased by 164.1%[18] - Digital Paid Weeks for the three months ended December 28, 2024, were 37,595, down 8.3% from 41,010 in the same period of 2023[40] Profitability and Margins - Gross Margin improved to 69.7%, up 906 basis points from the prior year, while Adjusted Gross Margin was 69.1%, an increase of 771 basis points[5] - Operating Income for Q4 2024 was $36.2 million, with an Operating Income Margin of 19.6%, up 2,256 basis points year-over-year[5] - Adjusted Operating Income for the full year was $104.8 million, reflecting a 17.2% increase compared to the previous year[12] - Gross Margin in fiscal 2024 improved to 67.8%, up from 59.5% in the prior year, driven by cost-saving initiatives[18] - Adjusted Operating Income in fiscal 2024 was $104.8 million, compared to $89.5 million in the prior year, indicating effective cost management[18] Net Income and Loss - The company reported a Net Loss of $345.7 million for the full year, including $293.2 million of non-cash impairment charges[12] - Net Income in Q4 2024 was $25.1 million compared to a Net Loss of $88.1 million in the prior year period, reflecting a strong turnaround[13] - Diluted Net Loss Per Share in fiscal 2024 was $4.34, compared to a loss of $1.46 in the prior year, highlighting ongoing challenges[18] - Net loss for the twelve months ended December 28, 2024, was $345,701, compared to a net loss of $112,255 in 2023, reflecting a significant increase in losses[34] - The net loss for 2024 is $345,701, with an adjusted net loss of $32,995, representing a 208.0% increase in losses compared to 2023[60] Cost Management and Restructuring - The company aims to achieve $100 million in run-rate cost savings by the end of 2025, focusing on disciplined cost management[6] - The company has incurred restructuring charges of $21,893 associated with the 2023 restructuring plan, impacting overall financial performance[58] - The company incurred $2,231 in restructuring charges related to the 2024 plan during Q4 2024[63] - The company is focusing on restructuring efforts to improve operational efficiency and reduce costs in the upcoming fiscal year[58] Cash and Liquidity - Cash and cash equivalents balance as of December 28, 2024, was $53.0 million, providing liquidity for future operations[16] - Cash and cash equivalents at the end of the period were $56,520, a decrease from $109,366 at the beginning of the period, reflecting a net decrease of $52,846[38] Future Outlook - The Company is not providing full year fiscal 2025 guidance at this time, indicating uncertainty in future performance[17] - Future outlook indicates a commitment to market expansion and potential new product development to drive revenue growth[58]

Core Insights - WW International, Inc. reported a decline in revenues for Q4 2024, with net revenues of $184.4 million, down 10.5% year-over-year, primarily due to lower subscription revenues and a significant drop in other revenues [4][11] - The company has appointed Tara Comonte as the permanent President and CEO, effective February 26, 2025, indicating a leadership transition during a critical period for the business [1][2] - The company is focusing on cost management and aims to achieve $100 million in run-rate cost savings by the end of 2025, which is expected to strengthen its financial foundation for long-term growth [3][11] Q4 2024 Financial Highlights - Subscription revenues decreased by 7.3% to $181.7 million, while other revenues fell by 72.8% to $2.7 million, leading to a total revenue decline of 10.5% [4][11] - Gross profit increased to $128.5 million, up 2.9% year-over-year, with a gross margin of 69.7%, reflecting improved cost management [4][11] - Operating income was reported at $36.2 million, a significant recovery from an operating loss of $6.0 million in the prior year, indicating effective cost-saving measures [4][11] Full Year Fiscal 2024 Financial Highlights - Total revenues for fiscal 2024 were $785.9 million, down 11.6% from the previous year, driven by challenges in recruitment and a decline in other revenues due to the closure of the consumer products business [10][22] - The company reported a net loss of $345.7 million for the year, compared to a net loss of $112.3 million in the prior year, largely due to non-cash impairment charges [10][22] - Adjusted operating income for the year was $104.8 million, up 17.2% from the previous year, demonstrating resilience in core operations despite overall losses [10][22] Subscriber Metrics - End of period subscribers decreased by 12.2% to 3.3 million, with declines in digital and workshop subscriptions, although clinical subscribers increased by 37.8% to 92,000 [11][22] - Total paid weeks fell by 9.9%, primarily due to declines in digital and workshop subscriptions, while clinical paid weeks grew by 53.3% [11][22] Strategic Focus - The company is navigating significant industry transitions and is committed to balancing growth investments with its capital structure realities [3][11] - The focus remains on enhancing the clinical business, which has shown strong growth, particularly in subscription revenues, which increased by 57.9% year-over-year [11][22]